Hanyu Pharmaceutical (300199.SZ): Caprost aminotriol injection obtained drug registration certificate

Zhitongcaijing · 2d ago

According to the Zhitong Finance App, Hanyu Pharmaceutical (300199.SZ) issued an announcement. Gansu Chengji Biopharmaceutical Co., Ltd. (hereinafter referred to as “Chengji Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for caprost and tromethotriol injections issued by the State Drug Administration. Caprost and tromethotriol injection is a prostaglandin-type drug. It is mainly used to treat postpartum hemorrhage caused by weak contractions. It is a clinically commonly used postpartum hemostatic drug.

This time, the caprost aminotriol injection obtained a drug registration certificate, which has enriched the product pipeline of the company and its subsidiary Chengji Pharmaceutical in the field of obstetrics and gynecology, which is conducive to enhancing the company's competitiveness in the gynecological hemostatic drug market. The company will promote the launch and sale of this product as soon as possible in accordance with relevant requirements.